Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | HTR1B | P28222 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7391903 | 0.98 | KCNA3 (0.76) | KCNA3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8767116 | 0.98 | KCNA3 (0.76) | KCNA3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20530581 | 0.98 | KCNA3 (0.76) | KCNA3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1544950 | 0.92 | KCNA3 (0.75) | KCNA3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7589672 | 0.89 | LTA4H (0.67) | KCNA3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1490164 | 0.89 | KCNA3 (1.00) | KCNA3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9786536 | 0.88 | KCNA3 (0.68) | KCNA3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9826063 | 0.88 | DRD2 (0.71) | KCNA3DRD2DRD4DRD3LTA4H | |
| SCHEMBL43271 | 0.87 | KCNA3 (0.67) | KCNA3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2512157 | 0.87 | KCNA3 (0.94) | KCNA3HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368194-B | Method for producing (meth) acryloyl group-terminated polyisobutylene polymer | 株式会社钟化 | 2021-03-19 | — | — | CN | disclosed |
| US-10604598-B2 | Method of producing (meth)acryloyl-terminated polyisobutylene polymer | KANEKA CORPORATION (JP) | 2020-03-31 | — | — | US | disclosed |
| US-20180362676-A1 | METHOD OF PRODUCING (METH)ACRYLOYL-TERMINATED POLYISOBUTYLENE POLYMER | KANEKA CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3388454-A1 | METHOD OF PRODUCING (METH)ACRYLOYL-TERMINATED POLYISOBUTYLENE POLYMER | Kaneka Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-7638535-B2 | (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-7452889-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-0817787-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0638064-B1 | SUBSTITUTED 1,1,2-TRIPHENYLBUTENES AND THEIR USE IN THE TREATMENT AND DIAGNOSIS OF CANCER | BRITISH TECH GROUP (GB) | 1997-08-13 | — | — | EP | disclosed |
| US-5589500-A | TREATMENT OF TUMORS OR ANTICARCINOGENIC AGENTS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-12-31 | — | — | US | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0638064-A1 | SUBSTITUTED 1,1,2-TRIPHENYLBUTENES AND THEIR USE IN THE TREATMENT AND DIAGNOSIS OF CANCER. | BRITISH TECH GROUP (GB) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993022275-A1 | SUBSTITUTED 1,1,2-TRIPHENYLBUTENES AND THEIR USE IN THE TREATMENT AND DIAGNOSIS OF CANCER | BRITISH TECHNOLOGY GROUP LTD (GB) | 1993-11-11 | — | — | WO | disclosed |
| US-4981619-A | CARBONYLATION, REDUCTION, FROM HALIDES | RHONE POULENC SPECIALITIES CHIMIQUES (FR) | 1991-01-01 | — | — | US | disclosed |
| EP-0214793-B1 | (2-CYANO-2-ARYLETHYL)PYRIDINES, THEIR PREPARATION AND USE AS FUNGICIDES | ROHM AND HAAS COMPANY (US) | 1990-06-13 | — | — | EP | disclosed |
| US-4933339-A | PHYTOPATHOGENS | ROHM AND HAAS COMPANY (US) | 1990-06-12 | — | — | US | disclosed |
| US-4386091-A | PSYCHOLOGICAL DISORDERS | MEAD JOHNSON & COMPANY (US) | 1983-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | KCNA3 39/4885HDAC3 475/4885HDAC4 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.